MT110: A novel bispecific single-chain antibody construct with high efficacy in eradicating established tumors

Adrain, 2004, Molecular ordering of the caspase activation cascade initiated by the CTL/NK protease granzyme B, J. Biol. Chem., 280, 4663, 10.1074/jbc.M410915200 Antunes, 2003, Trends and patterns of cancer mortality in European countries, Eur. J. Cancer Prev., 12, 367, 10.1097/00008469-200310000-00004 Appel, 2000, Kinetics of T-cell receptor binding by bivalent HLA-DR. Peptide complexes that activate antigen-specific human T-cells, J. Biol. Chem., 275, 312, 10.1074/jbc.275.1.312 Baeuerle, 2003, Bispecific antibodies for polyclonal T-cell engagement, Curr. Opin. Mol. Ther., 5, 413 Balzar, 1999, The biology of the 17-1A antigen (Ep-CAM), J. Mol. Med., 77, 699, 10.1007/s001099900038 Cartron, 2002, Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene, Blood, 99, 754, 10.1182/blood.V99.3.754 Clynes, 2000, Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets, Nat. Med., 6, 443, 10.1038/74704 Cochlovius, 2000, Treatment of human B cell lymphoma xenografts with a CD3×CD19 diabody and T cells, J. Immunol., 165, 888, 10.4049/jimmunol.165.2.888 Dall’Ozzo, 2004, Rituximab-dependent cytotoxicity by natural killer cells: influence of FCGR3A polymorphism on the concentration–effect relationship, Cancer Res., 64, 4664, 10.1158/0008-5472.CAN-03-2862 Davis, 2004, The radioisotope contributes significantly to the activity of radioimmunotherapy, Clin. Cancer Res., 10, 7792, 10.1158/1078-0432.CCR-04-0756 de Bono, 2004, ING-1, a monoclonal antibody targeting Ep-CAM in patients with advanced adenocarcinomas, Clin. Cancer Res., 10, 7555, 10.1158/1078-0432.CCR-04-0729 De Visser, 2003, CD8+ T cell tolerance and cancer immunotherapy, J. Immunother., 26, 1, 10.1097/00002371-200301000-00001 Dreier, 2003, T cell costimulus-independent and very efficacious inhibition of tumor growth in mice bearing subcutaneous or leukemic human B cell lymphoma xenografts by a CD19-/CD3-bispecific single-chain antibody construct, J. Immunol., 170, 4397, 10.4049/jimmunol.170.8.4397 Dreier, 2002, Extremely potent, rapid and costimulation-independent cytotoxic T-cell response against lymphoma cells catalyzed by a single-chain bispecific antibody, Int. J. Cancer, 100, 690, 10.1002/ijc.10557 Dudley, 2003, Adoptive-cell-transfer therapy for the treatment of patients with cancer, Nat. Rev. Cancer, 3, 666, 10.1038/nrc1167 Dudley, 2005, Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma, J. Clin. Oncol., 23, 2346, 10.1200/JCO.2005.00.240 Faulkner, 2004, BEAM-alemtuzumab reduced-intensity allogeneic stem cell transplantation for lymphoproliferative diseases: GVHD, toxicity, and survival in 65 patients, Blood, 103, 428, 10.1182/blood-2003-05-1406 Flieger, 2000, A bispecific single-chain antibody directed against EpCAM/CD3 in combination with the cytokines interferon alpha and interleukin-2 efficiently retargets T and CD3+CD56+ natural-killer-like T lymphocytes to EpCAM-expressing tumor cells, Cancer Immunol. Immunother., 49, 441, 10.1007/s002620000130 Foss, 2002, Immunologic mechanisms of antitumor activity, Semin. Oncol., 29, 5, 10.1053/sonc.2002.33076 Furman, 2004, Epratuzumab in non-Hodgkin's lymphomas, Curr. Treat Options Oncol., 5, 283, 10.1007/s11864-004-0019-1 Gennari, 2004, Pilot study of the mechanism of action of preoperative trastuzumab in patients with primary operable breast tumors overexpressing HER2, Clin. Cancer Res., 10, 5650, 10.1158/1078-0432.CCR-04-0225 Glimcher, 2004, Recent developments in the transcriptional regulation of cytolytic effector cells, Nat. Rev. Immunol., 4, 900, 10.1038/nri1490 Grillo-Lopez, 1999, Overview of the clinical development of rituximab: first monoclonal antibody approved for the treatment of lymphoma, Semin. Oncol., 26, 66 Hale, 1998, Improving the outcome of bone marrow transplantation by using CD52 monoclonal antibodies to prevent graft-versus-host disease and graft rejection, Blood, 92, 4581, 10.1182/blood.V92.12.4581 Hoel, 1992, Trends in cancer mortality in 15 industrialized countries, 1969–1986, J. Natl. Cancer Inst., 84, 313, 10.1093/jnci/84.5.313 Howe, 2001, Annual report to the nation on the status of cancer (1973 through 1998), featuring cancers with recent increasing trends, J. Natl. Cancer Inst., 93, 824, 10.1093/jnci/93.11.824 Hurwitz, 2004, Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer, N. Engl. J. Med., 350, 2335, 10.1056/NEJMoa032691 Jones, 2004, The development of a modified human IFN-alpha2b linked to the Fc portion of human IgG1 as a novel potential therapeutic for the treatment of hepatitis C virus infection, J. Interferon Cytokine Res., 24, 560, 10.1089/jir.2004.24.560 Khalil, 2003, Targeting epidermal growth factor receptor: novel therapeutics in the management of cancer, Expert Rev. Anticancer Ther., 3, 367, 10.1586/14737140.3.3.367 Kim, 2003, Identification of epithelial cell adhesion molecule autoantibody in patients with ovarian cancer, Clin. Cancer Res., 9, 4782 Kottaridis, 2000, In vivo CAMPATH-1H prevents graft-versus-host disease following nonmyeloablative stem cell transplantation, Blood, 96, 2419, 10.1182/blood.V96.7.2419 Kufer, 2004, A revival of bispecific antibodies, Trends Biotechnol., 22, 238, 10.1016/j.tibtech.2004.03.006 Kufer, 1997, Construction and biological activity of a recombinant bispecific single-chain antibody designed for therapy of minimal residual colorectal cancer, Cancer Immunol. Immunother., 45, 193, 10.1007/s002620050431 Leonard, 2004, Epratuzumab, a humanized anti-CD22 antibody, in aggressive non-Hodgkin's lymphoma: phase I/II clinical trial results, Clin. Cancer Res., 10, 5327, 10.1158/1078-0432.CCR-04-0294 Loffler, 2003, Efficient elimination of chronic lymphocytic leukaemia B cells by autologous T cells with a bispecific anti-CD19/anti-CD3 single-chain antibody construct, Leukemia, 17, 900, 10.1038/sj.leu.2402890 Loffler, 2000, A recombinant bispecific single-chain antibody, CD19×CD3, induces rapid and high lymphoma-directed cytotoxicity by unstimulated T lymphocytes, Blood, 95, 2098, 10.1182/blood.V95.6.2098 Mack, 1997, Biologic properties of a bispecific single-chain antibody directed against 17-1A (EpCAM) and CD3: tumor cell-dependent T cell stimulation and cytotoxic activity, J. Immunol., 158, 3965, 10.4049/jimmunol.158.8.3965 Mack, 1995, A small bispecific antibody construct expressed as a functional single-chain molecule with high tumor cell cytotoxicity, Proc. Natl. Acad. Sci. U.S.A., 92, 7021, 10.1073/pnas.92.15.7021 Maloney, 2001, Mechanism of action of rituximab, Anticancer Drugs, 12, S1 Matar, 2004, Combined epidermal growth factor receptor targeting with the tyrosine kinase inhibitor gefitinib (ZD1839) and the monoclonal antibody cetuximab (IMC-C225): superiority over single-agent receptor targeting, Clin. Cancer Res., 10, 6487, 10.1158/1078-0432.CCR-04-0870 Moldenhauer, 1987, Epithelium-specific surface glycoprotein of Mr 34,000 is a widely distributed human carcinoma marker, Br. J. Cancer, 56, 714, 10.1038/bjc.1987.276 Momburg, 1987, Immunohistochemical study of the expression of a Mr 34,000 human epithelium-specific surface glycoprotein in normal and malignant tissues, Cancer Res., 47, 2883 Mosolits, 2004, Vaccination with Ep-CAM protein or anti-idiotypic antibody induces Th1-biased response against MHC class I- and II-restricted Ep-CAM epitopes in colorectal carcinoma patients, Clin. Cancer Res., 10, 5391, 10.1158/1078-0432.CCR-04-0425 Munz, 2004, The carcinoma-associated antigen EpCAM upregulates c-myc and induces cell proliferation, Oncogene, 23, 5748, 10.1038/sj.onc.1207610 Nagler, 1997, Enhancement of megakaryocytopoiesis by Campath-1G-treated natural killer cells, Bone Marrow Transplant., 20, 525, 10.1038/sj.bmt.1700952 Naundorf, 2002, In vitro and in vivo activity of MT201, a fully human monoclonal antibody for pancarcinoma treatment, Int. J. Cancer, 100, 101, 10.1002/ijc.10443 Offner, 2006, Induction of regular cytolytic T cell synapses by bispecific single-chain antibody constructs on MHC class I-negative tumor cells, Mol. Immunol., 43, 763, 10.1016/j.molimm.2005.03.007 Osta, 2004, EpCAM is overexpressed in breast cancer and is a potential target for breast cancer gene therapy, Cancer Res., 64, 5818, 10.1158/0008-5472.CAN-04-0754 Pegram, 2004, Results of two open-label, multicenter phase II studies of docetaxel, platinum salts, and trastuzumab in HER2-positive advanced breast cancer, J. Natl. Cancer Inst., 96, 759, 10.1093/jnci/djh133 Porakishvili, 2004, Cytotoxic CD4+ T cells in patients with B cell chronic lymphocytic leukemia kill via a perforin-mediated pathway, Haematologica, 89, 435 Prang, 2005, Cellular and complement-dependent cytotoxicity of Ep-CAM specific monoclonal antibody MT201 against breast cancer cell lines, Br. J. Cancer, 92, 342, 10.1038/sj.bjc.6602310 Raum, 2001, Anti-self antibodies selected from a human IgD heavy chain repertoire: a novel approach to generate therapeutic human antibodies against tumor-associated differentiation antigens, Cancer Immunol. Immunother., 50, 141, 10.1007/PL00006684 Riethmuller, 1994, Randomised trial of monoclonal antibody for adjuvant therapy of resected Dukes’ C colorectal carcinoma. German Cancer Aid 17-1A Study Group, Lancet, 343, 1177, 10.1016/S0140-6736(94)92398-1 Schlereth, 2005, Eradication of tumors from a human colon cancer cell line and from ovarian cancer metastases in immunodeficient mice by a single-chain Ep-CAM-/CD3-bispecific antibody construct, Cancer Res., 65, 2882, 10.1158/0008-5472.CAN-04-2637 Smith, 2003, Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance, Oncogene, 22, 7359, 10.1038/sj.onc.1206939 Spizzo, 2002, Prognostic significance of Ep-CAM AND Her-2/neu overexpression in invasive breast cancer, Int. J. Cancer, 98, 883, 10.1002/ijc.10270 Spizzo, 2004, High Ep-CAM expression is associated with poor prognosis in node-positive breast cancer, Breast Cancer Res. Treat., 86, 207, 10.1023/B:BREA.0000036787.59816.01 Vogel, 2001, First-line, single-agent Herceptin(trastuzumab) in metastatic breast cancer: a preliminary report., Eur. J. Cancer, 37, S25, 10.1016/S0959-8049(00)00405-6 Weng, 2003, Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma, J. Clin. Oncol., 21, 3940, 10.1200/JCO.2003.05.013 Wimberger, 2003, Efficient tumor cell lysis by autologous, tumor-resident T lymphocytes in primary ovarian cancer samples by an EP-CAM-/CD3-bispecific antibody, Int. J. Cancer, 105, 241, 10.1002/ijc.11056 Winter, 2003, Expression of Ep-CAM shifts the state of cadherin-mediated adhesions from strong to weak, Exp. Cell. Res., 285, 50, 10.1016/S0014-4827(02)00045-9 Wong, 1990, The mechanism of anti-CD3 monoclonal antibodies. Mediation of cytolysis by inter-T cell bridging, Transplantation, 50, 683, 10.1097/00007890-199010000-00030 Xiang, 1992, Production of hybrid bispecific antibody recognizing human colorectal carcinoma and CD3 antigen, Mol. Biother., 4, 15